Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06186856 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Epidemiological Data on Mast Cell Pathologies in France

Study acronym: DATAMAST
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 2 of 21 sitesv10
  2. Start date: Jan 1, 2024 to Nov 1, 2024
    • Study sites: 20 to 21
    v9
  3. Study sites: 15 to 20v8
  4. Site details revised at 1 of 15 sitesv7
  5. Study sites: 14 to 15v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 13 to 14v5
  2. Study sites: 12 to 13v4
  3. Study sites: 2 to 12
    • Eligibility criteria shortened, about 5 words
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Mast cell disorders constitute a heterogeneous group of diseases, including : * mastocytosis, i.e. cutaneous, indolent and severe forms of the disease, such as aggressive mastocytosis and mast cell leukemia) ; * mast cell-associated diseases such as mast cell activation syndrome (idiopathic, secondary or clonal), affecting both children and adults. No epidemiological data are currently available in France. In France, medical care of mast cell disorders is mainly provided by a rare disease network (CEREMAST), whose CRMR is located at the Necker Enfants Malades hospital in Paris. A total of 20 centers are located throughout France. Our aim is to use this network to study patients suffering from these diseases. The overall aim of the study is to improve the understanding, diagnosis, prognosis, recognition and management of patients with mastocytosis.
Trial Details
NCT Number NCT06186856
Lead Sponsor Imagine Institute
Conditions
(from sponsor)		 Mast Cell Disorder
Related terms Mast Cell Activation Disorders, Mastocytosis
Enrollment 13,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov